Loading…
Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model
Objectives To measure the oral bioavailability of estetrol (E4) in rats relative to its subcutaneous administration and to test the bone-sparing effect of oral E4 compared to that of ethinylestradiol (EE). Methods In the bioavailability study, E4 was administered as a single dose of 0.05, 0.5 or 5.0...
Saved in:
| Published in: | Climacteric : the journal of the International Menopause Society 2008, Vol.11 (S1), p.2-14 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c457t-c5cafad38ea31fc44ba7fc277ee8c3021c1578f5ea908e67afceb272c70e99963 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c457t-c5cafad38ea31fc44ba7fc277ee8c3021c1578f5ea908e67afceb272c70e99963 |
| container_end_page | 14 |
| container_issue | S1 |
| container_start_page | 2 |
| container_title | Climacteric : the journal of the International Menopause Society |
| container_volume | 11 |
| creator | Coelingh Bennink, H. J. T. Heegaard, A.-M. Visser, M. Holinka, C. F. Christiansen, C. |
| description | Objectives To measure the oral bioavailability of estetrol (E4) in rats relative to its subcutaneous administration and to test the bone-sparing effect of oral E4 compared to that of ethinylestradiol (EE).
Methods In the bioavailability study, E4 was administered as a single dose of 0.05, 0.5 or 5.0 mg kg orally or subcutaneously to female rats. Plasma was analyzed using an LC-MS MS method.
The bone study was conducted in 3-month-old female rats assigned to the following seven treatment groups of ten animals each: no treatment; sham-operated + vehicle; bilaterally ovariectomized (OVX) + vehicle; OVX + E4 0.1, 0.5, or 2.5 mg kg day and OVX + EE 0.1 mg kg day. Once-daily treatment by oral gavage was given for 4 weeks and the following measurements were performed: serum osteocalcin, bone mineral density, bone mineral content and bone mineral area of lumbar vertebrae L3-L6, peripheral quantitative computed tomography of the left tibiae and the biomechanical properties of the distal femora.
Results Oral bioavailability of E4, relative to that of subcutaneous dosing, was 70% and above at the 0.05 and 0.5 mg kg doses based on the AUC0-t last. Subcutaneous dosing provided significantly higher E4 levels at the 1-h time point only, and was comparable to oral dosing after 0.5, 2, 4 and 8 h.
In the bone study, E4 dose-dependently and significantly (1) inhibited the OVX-related increase in osteocalcin levels, (2) increased bone mineral density and content, and (3) increased bone strength, all attenuated by ovariectomy. In this rat model, the relative potency of the highest dose of E4 (2.5 mg kg day) was comparable to the EE dose, used as positive control.
Conclusions Estetrol exhibits high oral bioavailability in the rat, a species considered relevant for pharmacological studies that are predictive for effects on human bone. Oral administration of E4 conveys dose-dependent bone-sparing effects of high-quality bone in estrogen-depleted OVX rats. Based on its bone-sparing effects, its oral bioavailability and its preclinical safety and efficacy profile, E4 may be superior to other estrogens and is a potential drug for the prevention of osteoporosis in postmenopausal women. |
| doi_str_mv | 10.1080/13697130701798692 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_journals_198680114</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1503390301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-c5cafad38ea31fc44ba7fc277ee8c3021c1578f5ea908e67afceb272c70e99963</originalsourceid><addsrcrecordid>eNp9kF1rFTEQhoMo_dIf4I0EL7xbzWz2JFnaGyl-QaEg7XWYzU7alOzmmOypnH9v9ByoVfRqZpjnfZl5GXsJ4i0II96BVL0GKbQA3RvVt0_YEXRaNnXZPa193TcV0IfsuJQ7IUBKUAfsEEynOgHqiH29zBj5EBLeY4g4hBiWLcd55EOaqSlrzGG-4eQ9uaXw5DmVhZacIg9z5XiqY1qnnEoofEojxefsmcdY6MW-nrDrjx-uzj83F5efvpy_v2hct9JL41YOPY7SEErwrusG1N61WhMZJ0ULDlba-BVhLwwpjd7R0OrWaUF93yt5wt7sfNc5fdvUs-wUiqMYcaa0KVb1YFr1C3z9B3iXNnmut1mosRkB0FUIdpCrr5RM3q5zmDBvLQj7M237V9pV82pvvBkmGh8U-3grcLYDwuxTnvB7ynG0C25jyj7j7EKx8n_-p4_kt4RxuXWY6bcP_qn-Ae0MoD0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198680114</pqid></control><display><type>article</type><title>Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Coelingh Bennink, H. J. T. ; Heegaard, A.-M. ; Visser, M. ; Holinka, C. F. ; Christiansen, C.</creator><creatorcontrib>Coelingh Bennink, H. J. T. ; Heegaard, A.-M. ; Visser, M. ; Holinka, C. F. ; Christiansen, C.</creatorcontrib><description>Objectives To measure the oral bioavailability of estetrol (E4) in rats relative to its subcutaneous administration and to test the bone-sparing effect of oral E4 compared to that of ethinylestradiol (EE).
Methods In the bioavailability study, E4 was administered as a single dose of 0.05, 0.5 or 5.0 mg kg orally or subcutaneously to female rats. Plasma was analyzed using an LC-MS MS method.
The bone study was conducted in 3-month-old female rats assigned to the following seven treatment groups of ten animals each: no treatment; sham-operated + vehicle; bilaterally ovariectomized (OVX) + vehicle; OVX + E4 0.1, 0.5, or 2.5 mg kg day and OVX + EE 0.1 mg kg day. Once-daily treatment by oral gavage was given for 4 weeks and the following measurements were performed: serum osteocalcin, bone mineral density, bone mineral content and bone mineral area of lumbar vertebrae L3-L6, peripheral quantitative computed tomography of the left tibiae and the biomechanical properties of the distal femora.
Results Oral bioavailability of E4, relative to that of subcutaneous dosing, was 70% and above at the 0.05 and 0.5 mg kg doses based on the AUC0-t last. Subcutaneous dosing provided significantly higher E4 levels at the 1-h time point only, and was comparable to oral dosing after 0.5, 2, 4 and 8 h.
In the bone study, E4 dose-dependently and significantly (1) inhibited the OVX-related increase in osteocalcin levels, (2) increased bone mineral density and content, and (3) increased bone strength, all attenuated by ovariectomy. In this rat model, the relative potency of the highest dose of E4 (2.5 mg kg day) was comparable to the EE dose, used as positive control.
Conclusions Estetrol exhibits high oral bioavailability in the rat, a species considered relevant for pharmacological studies that are predictive for effects on human bone. Oral administration of E4 conveys dose-dependent bone-sparing effects of high-quality bone in estrogen-depleted OVX rats. Based on its bone-sparing effects, its oral bioavailability and its preclinical safety and efficacy profile, E4 may be superior to other estrogens and is a potential drug for the prevention of osteoporosis in postmenopausal women.</description><identifier>ISSN: 1369-7137</identifier><identifier>EISSN: 1473-0804</identifier><identifier>DOI: 10.1080/13697130701798692</identifier><identifier>PMID: 18464016</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Administration, Oral ; Animals ; Area Under Curve ; BIOAVAILABILITY ; Biological Availability ; BONE ; Bone and Bones - drug effects ; Bone and Bones - metabolism ; Bone density ; Bone Density - drug effects ; Bone Density Conservation Agents - pharmacokinetics ; Bones ; Dose-Response Relationship, Drug ; Drug dosages ; ESTETROL ; Estetrol - pharmacokinetics ; Female ; Hormones ; Injections, Subcutaneous - veterinary ; Intestinal Absorption ; Osteocalcin - blood ; OSTEOPOROSIS ; Ovariectomy ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Rodents</subject><ispartof>Climacteric : the journal of the International Menopause Society, 2008, Vol.11 (S1), p.2-14</ispartof><rights>2008 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2008</rights><rights>Copyright Taylor & Francis Ltd. 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-c5cafad38ea31fc44ba7fc277ee8c3021c1578f5ea908e67afceb272c70e99963</citedby><cites>FETCH-LOGICAL-c457t-c5cafad38ea31fc44ba7fc277ee8c3021c1578f5ea908e67afceb272c70e99963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,783,787,4032,27936,27937,27938</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18464016$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Coelingh Bennink, H. J. T.</creatorcontrib><creatorcontrib>Heegaard, A.-M.</creatorcontrib><creatorcontrib>Visser, M.</creatorcontrib><creatorcontrib>Holinka, C. F.</creatorcontrib><creatorcontrib>Christiansen, C.</creatorcontrib><title>Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model</title><title>Climacteric : the journal of the International Menopause Society</title><addtitle>Climacteric</addtitle><description>Objectives To measure the oral bioavailability of estetrol (E4) in rats relative to its subcutaneous administration and to test the bone-sparing effect of oral E4 compared to that of ethinylestradiol (EE).
Methods In the bioavailability study, E4 was administered as a single dose of 0.05, 0.5 or 5.0 mg kg orally or subcutaneously to female rats. Plasma was analyzed using an LC-MS MS method.
The bone study was conducted in 3-month-old female rats assigned to the following seven treatment groups of ten animals each: no treatment; sham-operated + vehicle; bilaterally ovariectomized (OVX) + vehicle; OVX + E4 0.1, 0.5, or 2.5 mg kg day and OVX + EE 0.1 mg kg day. Once-daily treatment by oral gavage was given for 4 weeks and the following measurements were performed: serum osteocalcin, bone mineral density, bone mineral content and bone mineral area of lumbar vertebrae L3-L6, peripheral quantitative computed tomography of the left tibiae and the biomechanical properties of the distal femora.
Results Oral bioavailability of E4, relative to that of subcutaneous dosing, was 70% and above at the 0.05 and 0.5 mg kg doses based on the AUC0-t last. Subcutaneous dosing provided significantly higher E4 levels at the 1-h time point only, and was comparable to oral dosing after 0.5, 2, 4 and 8 h.
In the bone study, E4 dose-dependently and significantly (1) inhibited the OVX-related increase in osteocalcin levels, (2) increased bone mineral density and content, and (3) increased bone strength, all attenuated by ovariectomy. In this rat model, the relative potency of the highest dose of E4 (2.5 mg kg day) was comparable to the EE dose, used as positive control.
Conclusions Estetrol exhibits high oral bioavailability in the rat, a species considered relevant for pharmacological studies that are predictive for effects on human bone. Oral administration of E4 conveys dose-dependent bone-sparing effects of high-quality bone in estrogen-depleted OVX rats. Based on its bone-sparing effects, its oral bioavailability and its preclinical safety and efficacy profile, E4 may be superior to other estrogens and is a potential drug for the prevention of osteoporosis in postmenopausal women.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Area Under Curve</subject><subject>BIOAVAILABILITY</subject><subject>Biological Availability</subject><subject>BONE</subject><subject>Bone and Bones - drug effects</subject><subject>Bone and Bones - metabolism</subject><subject>Bone density</subject><subject>Bone Density - drug effects</subject><subject>Bone Density Conservation Agents - pharmacokinetics</subject><subject>Bones</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug dosages</subject><subject>ESTETROL</subject><subject>Estetrol - pharmacokinetics</subject><subject>Female</subject><subject>Hormones</subject><subject>Injections, Subcutaneous - veterinary</subject><subject>Intestinal Absorption</subject><subject>Osteocalcin - blood</subject><subject>OSTEOPOROSIS</subject><subject>Ovariectomy</subject><subject>Random Allocation</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Rodents</subject><issn>1369-7137</issn><issn>1473-0804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp9kF1rFTEQhoMo_dIf4I0EL7xbzWz2JFnaGyl-QaEg7XWYzU7alOzmmOypnH9v9ByoVfRqZpjnfZl5GXsJ4i0II96BVL0GKbQA3RvVt0_YEXRaNnXZPa193TcV0IfsuJQ7IUBKUAfsEEynOgHqiH29zBj5EBLeY4g4hBiWLcd55EOaqSlrzGG-4eQ9uaXw5DmVhZacIg9z5XiqY1qnnEoofEojxefsmcdY6MW-nrDrjx-uzj83F5efvpy_v2hct9JL41YOPY7SEErwrusG1N61WhMZJ0ULDlba-BVhLwwpjd7R0OrWaUF93yt5wt7sfNc5fdvUs-wUiqMYcaa0KVb1YFr1C3z9B3iXNnmut1mosRkB0FUIdpCrr5RM3q5zmDBvLQj7M237V9pV82pvvBkmGh8U-3grcLYDwuxTnvB7ynG0C25jyj7j7EKx8n_-p4_kt4RxuXWY6bcP_qn-Ae0MoD0</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>Coelingh Bennink, H. J. T.</creator><creator>Heegaard, A.-M.</creator><creator>Visser, M.</creator><creator>Holinka, C. F.</creator><creator>Christiansen, C.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>2008</creationdate><title>Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model</title><author>Coelingh Bennink, H. J. T. ; Heegaard, A.-M. ; Visser, M. ; Holinka, C. F. ; Christiansen, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-c5cafad38ea31fc44ba7fc277ee8c3021c1578f5ea908e67afceb272c70e99963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Area Under Curve</topic><topic>BIOAVAILABILITY</topic><topic>Biological Availability</topic><topic>BONE</topic><topic>Bone and Bones - drug effects</topic><topic>Bone and Bones - metabolism</topic><topic>Bone density</topic><topic>Bone Density - drug effects</topic><topic>Bone Density Conservation Agents - pharmacokinetics</topic><topic>Bones</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug dosages</topic><topic>ESTETROL</topic><topic>Estetrol - pharmacokinetics</topic><topic>Female</topic><topic>Hormones</topic><topic>Injections, Subcutaneous - veterinary</topic><topic>Intestinal Absorption</topic><topic>Osteocalcin - blood</topic><topic>OSTEOPOROSIS</topic><topic>Ovariectomy</topic><topic>Random Allocation</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Rodents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Coelingh Bennink, H. J. T.</creatorcontrib><creatorcontrib>Heegaard, A.-M.</creatorcontrib><creatorcontrib>Visser, M.</creatorcontrib><creatorcontrib>Holinka, C. F.</creatorcontrib><creatorcontrib>Christiansen, C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Climacteric : the journal of the International Menopause Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coelingh Bennink, H. J. T.</au><au>Heegaard, A.-M.</au><au>Visser, M.</au><au>Holinka, C. F.</au><au>Christiansen, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model</atitle><jtitle>Climacteric : the journal of the International Menopause Society</jtitle><addtitle>Climacteric</addtitle><date>2008</date><risdate>2008</risdate><volume>11</volume><issue>S1</issue><spage>2</spage><epage>14</epage><pages>2-14</pages><issn>1369-7137</issn><eissn>1473-0804</eissn><abstract>Objectives To measure the oral bioavailability of estetrol (E4) in rats relative to its subcutaneous administration and to test the bone-sparing effect of oral E4 compared to that of ethinylestradiol (EE).
Methods In the bioavailability study, E4 was administered as a single dose of 0.05, 0.5 or 5.0 mg kg orally or subcutaneously to female rats. Plasma was analyzed using an LC-MS MS method.
The bone study was conducted in 3-month-old female rats assigned to the following seven treatment groups of ten animals each: no treatment; sham-operated + vehicle; bilaterally ovariectomized (OVX) + vehicle; OVX + E4 0.1, 0.5, or 2.5 mg kg day and OVX + EE 0.1 mg kg day. Once-daily treatment by oral gavage was given for 4 weeks and the following measurements were performed: serum osteocalcin, bone mineral density, bone mineral content and bone mineral area of lumbar vertebrae L3-L6, peripheral quantitative computed tomography of the left tibiae and the biomechanical properties of the distal femora.
Results Oral bioavailability of E4, relative to that of subcutaneous dosing, was 70% and above at the 0.05 and 0.5 mg kg doses based on the AUC0-t last. Subcutaneous dosing provided significantly higher E4 levels at the 1-h time point only, and was comparable to oral dosing after 0.5, 2, 4 and 8 h.
In the bone study, E4 dose-dependently and significantly (1) inhibited the OVX-related increase in osteocalcin levels, (2) increased bone mineral density and content, and (3) increased bone strength, all attenuated by ovariectomy. In this rat model, the relative potency of the highest dose of E4 (2.5 mg kg day) was comparable to the EE dose, used as positive control.
Conclusions Estetrol exhibits high oral bioavailability in the rat, a species considered relevant for pharmacological studies that are predictive for effects on human bone. Oral administration of E4 conveys dose-dependent bone-sparing effects of high-quality bone in estrogen-depleted OVX rats. Based on its bone-sparing effects, its oral bioavailability and its preclinical safety and efficacy profile, E4 may be superior to other estrogens and is a potential drug for the prevention of osteoporosis in postmenopausal women.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>18464016</pmid><doi>10.1080/13697130701798692</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1369-7137 |
| ispartof | Climacteric : the journal of the International Menopause Society, 2008, Vol.11 (S1), p.2-14 |
| issn | 1369-7137 1473-0804 |
| language | eng |
| recordid | cdi_proquest_journals_198680114 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Administration, Oral Animals Area Under Curve BIOAVAILABILITY Biological Availability BONE Bone and Bones - drug effects Bone and Bones - metabolism Bone density Bone Density - drug effects Bone Density Conservation Agents - pharmacokinetics Bones Dose-Response Relationship, Drug Drug dosages ESTETROL Estetrol - pharmacokinetics Female Hormones Injections, Subcutaneous - veterinary Intestinal Absorption Osteocalcin - blood OSTEOPOROSIS Ovariectomy Random Allocation Rats Rats, Sprague-Dawley Rodents |
| title | Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-11T09%3A13%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20bioavailability%20and%20bone-sparing%20effects%20of%20estetrol%20in%20an%20osteoporosis%20model&rft.jtitle=Climacteric%20:%20the%20journal%20of%20the%20International%20Menopause%20Society&rft.au=Coelingh%20Bennink,%20H.%20J.%20T.&rft.date=2008&rft.volume=11&rft.issue=S1&rft.spage=2&rft.epage=14&rft.pages=2-14&rft.issn=1369-7137&rft.eissn=1473-0804&rft_id=info:doi/10.1080/13697130701798692&rft_dat=%3Cproquest_infor%3E1503390301%3C/proquest_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c457t-c5cafad38ea31fc44ba7fc277ee8c3021c1578f5ea908e67afceb272c70e99963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=198680114&rft_id=info:pmid/18464016&rfr_iscdi=true |